New weapon targets common cancer marker in early human trial
NCT ID NCT07408258
Summary
This is a first-in-human study to test the safety and find the right dose of a new experimental drug called ONC-783. It will involve about 20 adults with advanced solid tumors, focusing on colorectal, ovarian, pancreatic, or breast cancers. The drug is designed to guide the body's own immune cells to attack cancer by targeting a specific marker found on many tumor cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Medical Center
New York, New York, 10032, United States
Contact
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.